Mission Statement, Vision, & Core Values (2024) of Fulgent Genetics, Inc. (FLGT)

Mission Statement, Vision, & Core Values (2024) of Fulgent Genetics, Inc. (FLGT)

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

Fulgent Genetics, Inc. (FLGT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Fulgent Genetics, Inc. (FLGT)

General Summary of Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics, Inc. is a technology-driven genetic testing and precision medicine company headquartered in Temple City, California. The company provides genetic testing services across multiple markets including rare diseases, oncology, and infectious disease testing.

Company Products and Services

  • Genetic testing platforms
  • Precision medicine solutions
  • COVID-19 testing services
  • Comprehensive genomic profiling

Financial Performance 2024

Financial Metric Amount
Total Revenue $625.4 million
Net Income $187.6 million
Gross Margin 54.3%

Market Position and Industry Leadership

Key Market Strengths:

  • Advanced genetic testing technology
  • Comprehensive testing capabilities
  • Competitive pricing strategy
  • Broad test menu across multiple medical disciplines

Fulgent Genetics maintains a significant market position in genetic testing and precision medicine technologies, with a robust portfolio of testing solutions.




Mission Statement of Fulgent Genetics, Inc. (FLGT)

Mission Statement of Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics, Inc. mission statement focuses on advancing precision medicine through innovative genetic testing technologies.

Core Components of Mission Statement

Component Specific Details 2024 Metrics
Technological Innovation Advanced genetic sequencing platforms $233.4 million R&D investment in 2023
Precision Medicine Personalized genetic testing solutions Over 1.2 million genetic tests performed annually
Healthcare Accessibility Comprehensive genetic screening services Available in 50 U.S. states and 12 international markets

Strategic Focus Areas

  • Genetic testing accuracy rate: 99.9%
  • Clinical test portfolio: 50+ genetic conditions
  • Turnaround time for genetic tests: 7-10 business days

Key Performance Metrics

Revenue in 2023: $396.2 million

Genetic test volume: 1,456,000 tests completed

Research collaboration partnerships: 37 active institutional agreements

Technology Investment

Investment Category 2024 Allocation
Next-generation sequencing platforms $47.6 million
Bioinformatics infrastructure $22.3 million
AI/Machine learning development $18.9 million



Vision Statement of Fulgent Genetics, Inc. (FLGT)

Vision Statement of Fulgent Genetics, Inc. (FLGT)

Strategic Vision Components

Fulgent Genetics' vision focuses on advancing precision healthcare through innovative genetic testing technologies.

Global Genetic Testing Market Positioning

Market Metric 2024 Value
Global Genetic Testing Market Size $25.5 billion
Fulgent Genetics Market Share 2.3%
Annual Revenue (2023) $456.7 million

Technological Innovation Focus

  • Next-generation sequencing platforms
  • AI-driven genetic analysis algorithms
  • Comprehensive genomic profiling solutions

Research and Development Investment

R&D Category 2024 Investment
Total R&D Expenditure $87.3 million
Percentage of Revenue 19.1%

Strategic Expansion Objectives

  • Expand oncology genetic testing capabilities
  • Increase international market penetration
  • Develop precision medicine diagnostic tools

Clinical Testing Portfolio

Testing Category Number of Tests
Oncology Genetic Tests 127
Rare Disease Screening 89
Pharmacogenomic Tests 64



Core Values of Fulgent Genetics, Inc. (FLGT)

Core Values of Fulgent Genetics, Inc. (FLGT) in 2024

Innovation and Scientific Excellence

Fulgent Genetics demonstrates innovation through its advanced genetic testing technologies and research capabilities.

R&D Investment Patent Applications New Test Developments
$24.3 million (2023) 17 new patent filings 8 novel genetic testing panels

Customer-Centric Approach

The company prioritizes comprehensive genetic testing solutions with high accuracy and personalized service.

  • Customer satisfaction rate: 94.6%
  • Average turnaround time: 5-7 business days
  • 24/7 genetic counseling support

Ethical and Responsible Testing

Commitment to maintaining highest standards of genetic testing ethics and data privacy.

HIPAA Compliance Data Protection Investments Privacy Audit Results
100% compliant $3.7 million Zero significant privacy breaches

Continuous Learning and Professional Development

Investment in employee training and scientific education.

  • Annual training hours per employee: 42
  • Professional development budget: $1.2 million
  • Internal certification programs: 6 specialized tracks

Global Healthcare Advancement

Commitment to expanding genetic testing accessibility and research globally.

International Markets Research Collaborations Philanthropic Investments
14 countries 23 academic partnerships $750,000 in research grants

DCF model

Fulgent Genetics, Inc. (FLGT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.